

Special Issue

Novel Antimicrobials and the Antimicrobial Activity: New Advances

Message from the Guest Editors

Antibiotic therapy is a key weapon in the eradication of infections throughout communities and hospital settings. Gram-negative carbapenem-resistant (GN-CRE) bacteria, vancomycin-resistant *Enterococcus faecium* (VRE) and methicillin-resistant *Staphylococcus aureus* (MRSA) cause the most deaths from infections worldwide. Phenotypic and genotypic knowledge of these multidrug-resistant microorganisms as well as their mechanisms of resistance are crucial. At the same time, the multidisciplinary development of new antibiotic molecules that can counteract antibiotic resistance is crucial in order to develop new treatment modalities for precision medicine that can overcome antibiotic resistance mechanisms. This Special Issue aims to provide up-to-date basic and clinical research, reviews and communications on new antibiotic molecules from microbiological, pharmacokinetic/pharmacodynamic and clinical points of view in order to strategically implement and stratify treatment plans for MDR infections.

Guest Editors

Dr. Davide Carcione

Dr. Luigi Principe

Dr. Cattaneo Dario

Deadline for manuscript submissions

15 September 2025



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/200633

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)